Expression and characterization of wild type and mutant recombinant human sulfamidase - Implications for Sanfilippo (mucopolysaccharidosis IIIA) syndrome

被引:33
|
作者
Perkins, KJ [1 ]
Byers, S [1 ]
Yogalingam, G [1 ]
Weber, B [1 ]
Hopwood, JJ [1 ]
机构
[1] Womens & Childrens Hosp, Dept Chem Pathol, Lysosomal Disorders Res Unit, N Adelaide, SA 5006, Australia
关键词
D O I
10.1074/jbc.274.52.37193
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Mucopolysaccharidosis IIIA (MPS-IIIA) is an autosomal recessive lysosomal storage disorder caused by the deficiency of sulfamidase (NS; EC 3.10.1.1), resulting in defective degradation and storage of heparan sulfate. This paper reports the production and characterization of monoclonal and polyclonal antibodies against recombinant human sulfamidase (rhNS) to quantitate and characterize normal and mutant sulfamidase produced from the wild type NS expression vector. Glycosylation and phosphorylation studies of immunoprecipitated rhNS show that all five potential glycosylation sites are utilized, with three high mannose/hybrid oligosaccharides and two simpler chains, with at least one functional mannose B-phosphate group. An NS quantification system was developed to determine the effect of the three most common and severe patient mutations: S66W (Italy), R74C (Poland), and R245H (The Netherlands), The quantity and specific activity of expressed mutant rhNS was significantly lower than expressed normal rhNS, with 0.3, 0.2, and 0.05% of normal rhNS produced and 15, 17, and 83% of normal specific activity for S66W, R74C, and R245H observed, respectively. The recent structural elucidation of N-acetylgalactosamine-4-sulfatase was utilized to postulate the effect on the structure-function relationship of NS, The characterization of normal and mutated rhNS has relevance for efficient diagnosis and therapeutic developments for MPS-IIIA patients.
引用
收藏
页码:37193 / 37199
页数:7
相关论文
共 50 条
  • [11] Cloning and expression of wild-type and mutant forms of recombinant human chromogranin A in Escherichia coli
    Thim-uam, Arthid
    Roytrakul, Sittiruk
    Attarat, Jongrak
    Yasothornsrikul, Sukkid
    PROCEEDINGS OF 48TH KASETSART UNIVERSITY ANNUAL CONFERENCE: SCIENCE, 2010, : 61 - 68
  • [12] Chemically modified recombinant human sulfamidase (SOBI003) in mucopolysaccharidosis IIIA patients: Results from an open, non-controlled, multicenter study
    Harmatz, Paul
    Muenzer, Joseph
    Ezgu, Fatih
    Dalen, Per
    Huledal, Gunilla
    Lindqvist, Daniel
    Gelius, Stefan Svensson
    Wiken, Margareta
    Onnestam, Kristin
    Broijersen, Anders
    MOLECULAR GENETICS AND METABOLISM, 2022, 136 (04) : 249 - 259
  • [13] ELECTROSTATIC INTERACTIONS IN WILD-TYPE AND MUTANT RECOMBINANT HUMAN MYOGLOBINS
    VARADARAJAN, R
    LAMBRIGHT, DG
    BOXER, SG
    BIOCHEMISTRY, 1989, 28 (09) : 3771 - 3781
  • [14] Expression in E-coli and purification of recombinant fragments of wild type and mutant human prion protein
    Corsaro, A
    Thellung, S
    Russo, C
    Villa, V
    Arena, S
    D'Adamo, MC
    Paludi, D
    Principe, DR
    Damonte, G
    Benatti, U
    Aceto, A
    Tagliavini, F
    Schettini, G
    Florio, T
    NEUROCHEMISTRY INTERNATIONAL, 2002, 41 (01) : 55 - 63
  • [15] Characterization of a Case of Pigmentary Retinopathy in Sanfilippo Syndrome Type IIIA Associated with Compound Heterozygous Mutations in the SGSH Gene
    Wilkin, Justin
    Kerr, Natalie C.
    Byrd, Kathryn W.
    Ward, Jewell C.
    Iannaccone, Alessandro
    OPHTHALMIC GENETICS, 2016, 37 (02) : 217 - 227
  • [16] Expression of recombinant wild-type and mutant β-Lactoglobulins in the yeast Pichia pastoris
    Wilson, C
    Quarrie, L
    Allan, GJ
    Flint, DJ
    Sawyer, L
    Holt, C
    INTERNATIONAL JOURNAL OF FOOD SCIENCE AND TECHNOLOGY, 1999, 34 (5-6): : 445 - 450
  • [17] Functional characterization of wild-type and mutant human sialin
    Morin, P
    Sagné, C
    Gasnier, B
    EMBO JOURNAL, 2004, 23 (23): : 4560 - 4570
  • [18] Interim results of Transpher A, a multicenter, single-dose clinical trial of UX111 gene therapy for Sanfilippo syndrome type A (mucopolysaccharidosis IIIA)
    Flanigan, Kevin M.
    Smith, Nicholas
    Luz Couce, Maria
    Rajan, Deepa
    Truxal, Kristen
    McBride, Kim L.
    de Castro Lopez, Maria Jose
    Fuller, Maria
    Taylor, John
    Del Campo, Ana B.
    Grachev, Igor
    Lau, Heather
    MOLECULAR GENETICS AND METABOLISM, 2023, 138 (02) : 43 - 43
  • [19] The mutation p.Ser298Pro in the sulphamidase gene (SGSH) is associated with a slowly progressive clinical phenotype in mucopolysaccharidosis type IIIA (Sanfilippo A syndrome)
    Meyer, Ann
    Kossow, Kai
    Gal, Andreas
    Steglich, Cordula
    Miihlhausen, Chris
    Ullrich, Kurt
    Braulke, Thomas
    Muschol, Nicole
    HUMAN MUTATION, 2008, 29 (05) : 770 - 770
  • [20] Updated results of Transpher A: multicenter, single-dose, phase 1/2 clinical trial of ABO-102 for Sanfilippo syndrome type A (mucopolysaccharidosis IIIA)
    Flanigan, Kevin
    Smith, Nicholas
    Couce, Maria
    Escolar, Maria
    Truxal, Kristen
    McBride, Kim
    de Castro, Maria
    Fuller, Maria
    Paneda, Astrid
    Ruiz, Juan
    MOLECULAR GENETICS AND METABOLISM, 2021, 132 : S133 - S134